Online inquiry

IVTScrip™ mRNA-Anti-KDR, CDP791(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5606MR)

This product GTTS-WQ5606MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets KDR gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002253.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3791
UniProt ID P35968
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-KDR, CDP791(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5606MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4922MR IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA C11D5.3 scFv-8A-F9Z CAR
GTTS-WQ9368MR IVTScrip™ mRNA-Anti-PDCD1, INCMGA-00012(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA INCMGA-00012
GTTS-WQ14762MR IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SGN-35
GTTS-WQ8183MR IVTScrip™ mRNA-Anti-FCGRT, HL161(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA HL161
GTTS-WQ8053MR IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA h2H12ec
GTTS-WQ4302MR IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BIIB-054
GTTS-WQ1401MR IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABT-981
GTTS-WQ5945MR IVTScrip™ mRNA-Anti-IGHE, CL-2C(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CL-2C
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW